[go: up one dir, main page]

CN1980883B - Process for preparing optically active alkyl succinic acid monoalkyl esters - Google Patents

Process for preparing optically active alkyl succinic acid monoalkyl esters Download PDF

Info

Publication number
CN1980883B
CN1980883B CN2005800228341A CN200580022834A CN1980883B CN 1980883 B CN1980883 B CN 1980883B CN 2005800228341 A CN2005800228341 A CN 2005800228341A CN 200580022834 A CN200580022834 A CN 200580022834A CN 1980883 B CN1980883 B CN 1980883B
Authority
CN
China
Prior art keywords
hydrogenation
alkyl
optically active
carried out
succinic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800228341A
Other languages
Chinese (zh)
Other versions
CN1980883A (en
Inventor
F·黑特歇
C·耶克尔
M·弗里德里克
R·帕切洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200510007750 external-priority patent/DE102005007750A1/en
Application filed by BASF SE filed Critical BASF SE
Priority claimed from PCT/EP2005/007289 external-priority patent/WO2006002999A2/en
Publication of CN1980883A publication Critical patent/CN1980883A/en
Application granted granted Critical
Publication of CN1980883B publication Critical patent/CN1980883B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2419Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member
    • B01J31/2428Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom
    • B01J31/2433Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2419Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/303Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60Reduction reactions, e.g. hydrogenation
    • B01J2231/64Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/645Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/821Ruthenium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/822Rhodium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/824Palladium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/827Iridium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/828Platinum
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/847Nickel
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The invention relates to a method for producing optically active alkyl succinic acid monoalkyl esters of formula , wherein D and E are H, C independently of one another1-C10Alkyl, R is C1-C10Alkyl, aryl or alkylaryl.

Description

制备旋光烷基琥珀酸单烷基酯的方法 Method for preparing optically active monoalkyl succinate

本发明涉及一种制备旋光烷基琥珀酸单烷基酯的新方法。The present invention relates to a new method for preparing monoalkyl optically active alkyl succinates.

现有技术current technology

迄今为止,还不能令人满意地获得一种由它们的直接不饱和前体通过不对称氢化而直接选择性地形成III型体系及其旋光对映体的路径。To date, a route to the direct and selective formation of type III systems and their optical antipodes from their directly unsaturated precursors by asymmetric hydrogenation has not been satisfactorily obtained.

Figure G2005800228341D00011
Figure G2005800228341D00011

这可以通过例如由衣康酸单甲基酯3制备(2R)-甲基琥珀酸4-甲基酯4来证实,其中衣康酸单甲基酯3可容易地以低成本获得。This can be demonstrated, for example, by the preparation of (2R)-methylsuccinic acid 4-methyl ester 4 from itaconate monomethyl ester 3, which is readily available at low cost.

K.Achiwa,Y.Ohga,Y.Itaka,Tetrahedron Lett.1978,19,4683在甲醇中获得了具有60%对映体过量(=ee=[对映体1含量-对映体2含量]/[对映体1含量+对映体2含量])的化合物4。K.Achiwa, Y.Ohga, Y.Itaka, Tetrahedron Lett.1978,19,4683 obtained in methanol with 60% enantiomeric excess (=ee=[enantiomer 1 content-enantiomer 2 content]/ [enantiomer 1 content + enantiomer 2 content]) compound 4.

W.C.Christopfel,B.D.Vineyard,J.Am.Chem.Soc.1979,101,4406在甲醇中获得了具有55%ee的化合物4。W. C. Christopfel, B. D. Vineyard, J. Am. Chem. Soc. 1979, 101, 4406 obtained compound 4 with 55% ee in methanol.

S.Saito,Y.Nakamura,Y.Morita,Chem.Pharm.Bull.1985,33,5284在苯/MeOH 1/4中获得了具有90%ee的化合物4。S. Saito, Y. Nakamura, Y. Morita, Chem. Pharm. Bull. 1985, 33, 5284 obtained compound 4 with 90% ee in benzene/MeOH 1/4.

H.Kawano,Y.Ishii,T.Ikariya,M.Saburi,S.Yoshikawa,TetrahedronLett.1987,28,1905在甲苯/THF中获得了具有60%ee的化合物4。H. Kawano, Y. Ishii, T. Ikariya, M. Saburi, S. Yoshikawa, Tetrahedron Lett. 1987, 28, 1905 obtained compound 4 with 60% ee in toluene/THF.

D.Carmichael,H.Doucet,J.M.Brown,Chem.Commun.1999,261 H.Kawano,T.Ikariya,Y.Ishii,M.Saburi,S.Yoshikawa et al.,J.Chem.Soc.Perkin Trans.1 1989,1571在甲醇中获得了具有94%ee的化合物4。D.Carmichael, H.Doucet, J.M.Brown, Chem.Commun.1999, 261 H.Kawano, T.Ikariya, Y.Ishii, M.Saburi, S.Yoshikawa et al., J.Chem.Soc.Perkin Trans. 1 1989, 1571 obtained compound 4 with 94% ee in methanol.

U.Berens,M.Burk,A.Gerlach(WO 00/27855;EP 1 127 061 B1)在甲醇中获得了具有95%ee的化合物4。U.Berens, M.Burk, A.Gerlach (WO 00/27855; EP 1 127 061 B1) obtained compound 4 with 95% ee in methanol.

因此,在无附加富集步骤的情况下,上述方法达到的光学纯度不能满足活性成分方面的要求,多数情况下的要求是对映体过量≥98%ee。Therefore, without an additional enrichment step, the optical purity achieved by the above method cannot meet the requirements in terms of active ingredients, which in most cases require an enantiomeric excess ≥ 98% ee.

能达到较高光学纯度的其它方法使用大量的催化剂,也就是低的底物/催化剂比率(s/c),这对于工业生产是不经济的;或者所选择的反应条件(特别是溶剂)从环境角度着眼或出于职业安全的原因是存在问题的。Other methods that can achieve higher optical purity use a large amount of catalyst, that is, a low substrate/catalyst ratio (s/c), which is not economical for industrial production; or the selected reaction conditions (especially the solvent) from It is problematic from an environmental perspective or for reasons of occupational safety.

M.Ostermeier,B.Brunner,C.Korff,G.Helmchen,Eur.J.Org.Chem.2003,3453在二氯甲烷中以200/1的s/c比率获得具有97.3%ee的化合物4,在C6H5CF3中同样以200/1的s/c比率达到了98.3%ee。在二氯乙烷中,以1000/1的s/c比率达到纯度99.3%ee。M. Ostermeier, B. Brunner, C. Korff, G. Helmchen, Eur. J. Org. Chem. 2003, 3453 Obtained compound 4 with 97.3% ee at s/c ratio of 200/1 in dichloromethane, In C 6 H 5 CF 3 , 98.3% ee was also achieved with a s/c ratio of 200/1. In dichloroethane, a purity of 99.3% ee was achieved at a s/c ratio of 1000/1.

出于上述原因,所有这些方法都不适合在工业规模上由能以低成本易于获得的烯烃前体一步直接合成旋光琥珀酸烷基酯。For the reasons mentioned above, all these methods are not suitable for direct one-step synthesis of optically active alkyl succinates on an industrial scale from olefinic precursors that are readily available at low cost.

发明目的purpose of invention

本发明的目的是提供一种制备旋光烷基琥珀酸单烷基酯的新方法,该方法使用少量的催化剂(s/c≥20,000/1),同时具有与环境协调的反应条件、完全的反应转化率和高光学收率(≥98%ee),因此能够进行高效、环境可接受的、成本有效的工业合成。The object of the present invention is to provide a new method for preparing optically active alkyl succinic acid monoalkyl esters, which uses a small amount of catalyst (s/c≥20,000/1), and has reaction conditions coordinated with the environment, complete reaction conversion and high optical yield (≥98%ee), thus enabling efficient, environmentally acceptable, cost-effective industrial synthesis.

发明内容Contents of the invention

我们已经发现了一种制备式(I)旋光烷基琥珀酸单烷基酯的方法,We have found a method for the preparation of optically active monoalkyl alkyl succinates of formula (I),

其中D和E彼此独立地为H、C1-C10烷基,wherein D and E are independently of each other H, C 1 -C 10 alkyl,

R为C1-C10烷基、芳基或烷基芳基,R is C 1 -C 10 alkyl, aryl or alkylaryl,

该方法在包含式(L)磷杂环戊烷配体(phospholane ligand)的催化剂存在下,The method is in the presence of a catalyst comprising a formula (L) phospholane ligand (phospholane ligand),

Figure G2005800228341D00032
Figure G2005800228341D00032

(L)(L)

其中:in:

R1和R2彼此独立地为C1-C6烷基、芳基、烷基芳基,R 1 and R 2 are independently of each other C 1 -C 6 alkyl, aryl, alkylaryl,

R1另外为氢, R is additionally hydrogen,

A为R1A for R 1 or

条件是B=在两个P原子之间具有1-5个碳原子的连接基(Iinker)或Cp-Fe-Cp,with the proviso that B=linker (Iinker) or Cp-Fe-Cp with 1-5 carbon atoms between two P atoms,

对映选择性地氢化式(II)化合物:Enantioselective hydrogenation of compounds of formula (II):

Figure G2005800228341D00041
Figure G2005800228341D00041

其中D、E和R具有上文所述的意义。wherein D, E and R have the meanings indicated above.

式(I)化合物是在各种情况下用来代表一种对映体(R或S)的旋光化合物。The compounds of formula (I) are optically active compounds which represent in each case one enantiomer (R or S).

对映选择性氢化在下文中用来指下述氢化:这种氢化不会获得相同程度的两种对映体,其中一种对映体(R或S)以高纯度、特别是以对映体过量98%、99%、99.5%的纯度形成。Enantioselective hydrogenation is used hereinafter to refer to a hydrogenation which does not yield the two enantiomers to the same extent, one of the enantiomers (R or S) in high purity, especially in the enantiomer Excesses of 98%, 99%, 99.5% purity were formed.

式(II)的起始化合物可由文献获知并且可容易地通过传统方法制备(对于D=E=H;R=Me,参见例如,A.R.Devi,S.Rajaram,Ind.J.Chem.2000,39B,294-296或R.C.Anand,V.A.Milhotra,J.Chem.Res.(S)1999,378-379或R.N.Ram,I.Charles,Tetrahedron 1997,53,7335-7340)。优选的起始化合物(II)是那些其中D和E彼此独立地具有下述意义的化合物:H、甲基、乙基、丙基、丁基、戊基、己基、庚基、辛基、壬基、癸基,其中所述烷基包括未支化和支化的异构体。特别优选的起始化合物是其中D和E为H和甲基的那些,尤其是其中D和E为H或D和E为甲基的那些。进一步优选的起始化合物(II)是其中D为H且E为丁基的那些。Starting compounds of formula (II) are known from the literature and can be easily prepared by conventional methods (for D=E=H; R=Me, see e.g. A.R. Devi, S. Rajaram, Ind. J. Chem. 2000, 39B , 294-296 or R.C.Anand, V.A.Milhotra, J.Chem.Res.(S) 1999, 378-379 or R.N.Ram, I.Charles, Tetrahedron 1997, 53, 7335-7340). Preferred starting compounds (II) are those in which D and E independently of one another have the following meanings: H, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl radical, decyl, wherein said alkyl includes unbranched and branched isomers. Particularly preferred starting compounds are those in which D and E are H and methyl, especially those in which D and E are H or D and E are methyl. Further preferred starting compounds (II) are those in which D is H and E is butyl.

基团R可以是C1-C10烷基,其中所述烷基中的各个H原子可进而被其它基团如OH、NH2、NO2、CN、F、Cl、Br、I取代。另外,R还可以是芳基如苯基、萘基;和烷基芳基如苄基,其中的芳基还可以进而被取代。优选的R是甲基、乙基、丙基、异丙基和叔丁基。R特别优选为甲基。The group R can be a C 1 -C 10 alkyl group, wherein each H atom in the alkyl group can in turn be substituted by other groups such as OH, NH 2 , NO 2 , CN, F, Cl, Br, I. In addition, R can also be an aryl group such as phenyl, naphthyl; and an alkylaryl group such as benzyl, wherein the aryl group can be further substituted. Preferred R are methyl, ethyl, propyl, isopropyl and tert-butyl. R is particularly preferably methyl.

所述催化剂包含选自Pd、Pt、Ru、Rh、Ni、Ir的金属原子。特别优选的催化剂具有作为金属原子的Rh、Ru或Ir,而且Rh催化剂特别适合本发明方法。The catalyst comprises metal atoms selected from Pd, Pt, Ru, Rh, Ni, Ir. Particularly preferred catalysts have Rh, Ru or Ir as the metal atom, and Rh catalysts are particularly suitable for the process according to the invention.

可优选用于制备所述催化剂的金属源是前体例如Pd2(DBA)3,Pd(Oac)2,[Rh(COD)Cl]2,[Rh(COD)2]]X,Rh(acac)(CO)2,RuCl2(COD),Ru(COD)(甲代烯丙基)2,Ru(Ar)Cl2,Ar=未取代和取代的芳基,[Ir(COD)Cl]2,[Ir(COD)2]X,Ni(烯丙基)X。还优选用NBD(=降冰片二烯)代替COD(=1,5-环辛二烯)。Metal sources which may preferably be used in the preparation of the catalyst are precursors such as Pd2 (DBA) 3 , Pd(Oac) 2 , [Rh(COD)Cl] 2 , [Rh(COD) 2 ]]X, Rh(acac )(CO) 2 , RuCl 2 (COD), Ru(COD)(methallyl) 2 , Ru(Ar)Cl 2 , Ar = unsubstituted and substituted aryl, [Ir(COD)Cl] 2 , [Ir(COD) 2 ]X, Ni(allyl)X. Preference is also given to substituting NBD (=norbornadiene) for COD (=1,5-cyclooctadiene).

在这些情况下X可以是本领域熟练技术人员公知并且可用于不对称合成的任何阴离子。X的实例是卤素例如Cl-、Br-、I-,BF4 -、ClO4 -、SbF6 -、PF6 -、CF3SO3 -、BAr4 -。X优选是BF4 -、CF3SO3 -、SbF6 -、ClO4 -,特别是BF4 -和CF3SO3 -X in these cases can be any anion known to the person skilled in the art and available for asymmetric synthesis. Examples of X are halogens such as Cl , Br , I , BF 4 , ClO 4 , SbF 6 , PF 6 , CF 3 SO 3 , BAr 4 . X is preferably BF 4 , CF 3 SO 3 , SbF 6 , ClO 4 , especially BF 4 and CF 3 SO 3 .

本发明方法的催化剂另外包含一种或多种式(L)的磷杂环戊烷配体。优选的取代基R1和R2为H、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、苄基。R1=H与R2=甲基的取代基组合是特别优选的。The catalyst of the process according to the invention additionally comprises one or more phospholane ligands of the formula (L). Preferred substituents R1 and R2 are H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, benzyl. The substituent combination of R 1 =H and R 2 =methyl is particularly preferred.

另外还优选的是其中两个R1形成桥的R1基团,例如亚异丙基或亚苄基。Also preferred are R 1 groups in which two R 1 form a bridge, such as isopropylidene or benzylidene.

在双磷杂环戊烷(diphospholanes)的情况下,优选的是下式表示的那些。In the case of diphospholanes, preferred are those represented by the following formulae.

Figure G2005800228341D00051
Figure G2005800228341D00051

特别优选的连接基B是其中n=1或2或m=0的那些。Particularly preferred linkers B are those in which n=1 or 2 or m=0.

特别优选的配体L是其中A代表另外一个磷杂环戊烷残基和连接基B的那些,其中B可以代表两个磷原子之间的1-5个碳原子的桥。所述两个磷原子之间的1-5个碳原子并不意味着B最多包含5个碳原子,而是两个磷原子之间的直接连接包含不超过5个碳原子。B可以是例如苯环,条件是两个磷原子在对位连接在苯环上。Particularly preferred ligands L are those in which A represents a further phospholane residue and a linker B, in which B may represent a bridge of 1 to 5 carbon atoms between two phosphorus atoms. Said 1-5 carbon atoms between two phosphorus atoms does not mean that B contains at most 5 carbon atoms, but that the direct link between two phosphorus atoms contains no more than 5 carbon atoms. B can be, for example, a benzene ring, provided that two phosphorus atoms are attached to the benzene ring in the para position.

但是,连接基B还可以是二茂铁型化合物,其由取代或未取代的且以夹心形式(Cp-Fe-Cp)包含Fe原子的环戊二烯基(Cp)组成,其中P原子键结到Cp基上。However, the linker B can also be a ferrocene-type compound consisting of a substituted or unsubstituted cyclopentadienyl group (Cp) containing Fe atoms in a sandwich form (Cp-Fe-Cp), where the P atoms bond Junction to Cp base.

特别优选的配体L为:Particularly preferred ligands L are:

Figure G2005800228341D00061
Figure G2005800228341D00061

本发明不仅包括由这些结构式表示的对映体,而且还包括它们的旋光对映体。The present invention includes not only the enantiomers represented by these structural formulas but also their optical antipodes.

关于Rophos催化剂的制备,参考EP 0889048,在此引用该专利供参考。For the preparation of Rophos catalysts, reference is made to EP 0889048, which is hereby incorporated by reference.

配体-金属配合物可通过包含不稳定配体(例如[RuCl2(COD)]n、[Rh(COD)2]BF4、[Rh(COD)2]CF3SO3、Rh(COD)2ClO4、[Ir(COD)Cl]2、对-甲基异丙基苯氯化钌二聚体)的铑、铱、钌、钯、铂、镍配合物反应以公知方式合成催化活性配合物制备。NBD还可代替COD用于制备配合物,具有良好效果。Ligand-metal complexes can be synthesized by including labile ligands such as [RuCl 2 (COD)] n , [Rh(COD) 2 ]BF 4 , [Rh(COD) 2 ]CF 3 SO 3 , Rh(COD) 2 ClO 4 , [Ir(COD)Cl] 2 , p-methylcymene ruthenium chloride dimer) rhodium, iridium, ruthenium, palladium, platinum, nickel complex reaction Synthesis of catalytically active complexes in a known manner material preparation. NBD can also be used to prepare complexes instead of COD, with good results.

正如本领域熟练技术人员所知道的,配合物(=预制催化剂precatalyst)可以在使用之前产生和分离,然后及时使用,或在实际氢化之前在反应容器内就地产生(见下述)。As is known to those skilled in the art, complexes (=precatalysts) can be generated and isolated prior to use and then used in time, or generated in situ in the reaction vessel prior to the actual hydrogenation (see below).

合适的溶剂是本领域熟练技术人员公知的所有用于不对称氢化的溶剂。优选的溶剂是低级烷基醇,例如甲醇、乙醇、异丙醇和甲苯、THF、乙酸乙酯。在本发明方法中,甲醇特别优选用作溶剂。Suitable solvents are all solvents known to the person skilled in the art for asymmetric hydrogenations. Preferred solvents are lower alkyl alcohols such as methanol, ethanol, isopropanol and toluene, THF, ethyl acetate. Methanol is particularly preferably used as solvent in the process of the invention.

本发明氢化通常在-20℃到150℃下进行,优选0-100℃,特别优选10-80℃。The hydrogenation according to the invention is usually carried out at a temperature of -20°C to 150°C, preferably 0-100°C, particularly preferably 10-80°C.

本发明方法在各种情况下使用≥20,000/1的底物/催化剂比率(s/c),结果获得≥98%ee。即使以110,000/1的s/c比率,也达到了98%ee。The process of the invention employs in each case a substrate/catalyst ratio (s/c) of >20,000/1, resulting in >98% ee. Even with a s/c ratio of 110,000/1, 98% ee was achieved.

催化剂的使用可通过适当固定催化剂进一步简化。The use of the catalyst can be further simplified by suitably immobilizing the catalyst.

对于本发明氢化方法,氢气压力可以在0.1巴-300巴的宽范围内变化。在1-200巴、优选1-100巴的压力范围内获得非常好的结果。For the hydrogenation process according to the invention, the hydrogen pressure can be varied within a wide range from 0.1 bar to 300 bar. Very good results are obtained in the pressure range of 1-200 bar, preferably 1-100 bar.

反应混合物利用本领域熟练技术人员公知的步骤处理。产物可以例如转化为羧酸盐,沉淀并进而从催化剂中除去,随后重新释放;可供选择的可能的方法是通过吸附将催化剂固定在床上,这样能够容易地进行色谱提纯。还可以通过蒸馏将催化剂从产物中移出。The reaction mixture is worked up using procedures well known to those skilled in the art. The product can, for example, be converted to the carboxylate, precipitated and thus removed from the catalyst, and then released again; an alternative possibility is to immobilize the catalyst on a bed by adsorption, which enables easy chromatographic purification. The catalyst can also be removed from the product by distillation.

通过产物中间转换为羧酸盐并简单地从反应混合物中沉淀可以将对映体过量提高到>99.5%。对此合适的碱是本领域熟练技术人员公知的所有碱,其中优选胺和胍作为中性碱(neutral bases),羧酸盐、碳酸盐、氢氧化物、氧化物作为金属碱。特别优选的金属碱是相应的锂化合物。The enantiomeric excess can be increased to >99.5% by intermediate conversion of the product to the carboxylate and simple precipitation from the reaction mixture. Suitable bases for this are all bases known to the person skilled in the art, among which amines and guanidines are preferred as neutral bases and carboxylates, carbonates, hydroxides, oxides as metallic bases. Particularly preferred metal bases are the corresponding lithium compounds.

其它优选的实施方式在附属的权利要求和实验部分描述。Other preferred embodiments are described in the appended claims and the experimental section.

实验部分Experimental part

实施例1Example 1

制备旋光甲基琥珀酸甲基酯(s/c 20,000/1)Preparation of optically active methyl methyl succinate (s/c 20,000/1)

在保护气体下将133mg(0.182mmol)(RophosARhCOD)CF3SO3(=预制催化剂)引入在4升(搪瓷)Pfaudler高压釜中的21ml甲醇中,并且加入溶于704ml甲醇中的526g(3.65mol)2-亚甲基琥珀酸4-单甲酯(=底物)。然后在40℃和5巴氢气下进行氢化。底物转化在4小时后完成(1H-NMR,500MHz)。通过气相色谱测定产物(2R)-甲基琥珀酸4-单甲酯的对映过量>98%(来源:BGB-Analytik,柱型:BGB-174,长度30m,内径:0.25ml,薄膜厚度:0.25μm,载气:氦、入口压力:2.35巴,温度:135℃,加热速率:1.2℃/min,R对映体的保留时间:23.3分钟,S对映体的保留时间:22.6分钟)。s/c比率为20,000∶1。133 mg (0.182 mmol) (RophosARhCOD) CF 3 SO 3 (=prefabricated catalyst) were introduced under protective gas into 21 ml methanol in a 4 liter (enamel) Pfaudler autoclave and 526 g (3.65 mol ) 4-monomethyl 2-methylenesuccinate (=substrate). Hydrogenation is then carried out at 40° C. and 5 bar hydrogen. Substrate conversion was complete after 4 hours ( 1 H-NMR, 500 MHz). The enantioexcess of the product (2R)-methylsuccinate 4-monomethyl ester determined by gas chromatography>98% (source: BGB-Analytik, column type: BGB-174, length 30m, internal diameter: 0.25ml, film thickness: 0.25 μm, carrier gas: helium, inlet pressure: 2.35 bar, temperature: 135 °C, heating rate: 1.2 °C/min, retention time of R enantiomer: 23.3 min, retention time of S enantiomer: 22.6 min). The s/c ratio was 20,000:1.

实施例2Example 2

制备旋光甲基琥珀酸甲基酯(s/c 40,000/1)Preparation of optically active methyl methyl succinate (s/c 40,000/1)

以40,000∶1的催化剂/底物比率s/c进行实施例1描述的反应。底物转化在4小时后完成。产物的对映体过量>98%。The reaction described in Example 1 was carried out at a catalyst/substrate ratio s/c of 40,000:1. Substrate conversion was complete after 4 hours. The enantiomeric excess of the product was >98%.

实施例3Example 3

制备旋光甲基琥珀酸甲基酯(s/c 110,000/1)Preparation of optically active methyl methyl succinate (s/c 110,000/1)

在保护气体下将5.73g(39.8mmol)2-亚甲基琥珀酸-4-单甲酯引入在50ml玻璃蒸压釜中的12ml甲醇中,并且加入0.12ml的6.6mg(RophosARhCOD)CF3SO3(=预制催化剂)于3ml甲醇中的溶液(0.00036mmol预制催化剂)。然后在60℃、5巴氢气下进行氢化。前体的转化在16小时后完成。该产物的对映体过量为98%。5.73 g (39.8 mmol) of 4-monomethyl 2-methylenesuccinate were introduced into 12 ml of methanol in a 50 ml glass autoclave under protective gas and 0.12 ml of 6.6 mg (RophosARhCOD) CF 3 SO was added Solution of 3 (=pre-catalyst) in 3 ml methanol (0.00036 mmol pre-catalyst). Hydrogenation is then carried out at 60° C. under 5 bar hydrogen. The conversion of the precursor was complete after 16 hours. The enantiomeric excess of the product is 98%.

实施例4Example 4

在工业规模上制备旋光甲基琥珀酸甲基酯,接着形成锂盐Preparation of optically active methyl methyl succinate on an industrial scale followed by lithium salt formation

在保护气体下将75kg亚甲基琥珀酸4-单甲酯(520.4mol)引入在1m3钢容器内的185升甲醇中。加入19.0g溶于2升甲醇中的(RophosARhCOD)CF3SO3(=26mmol预制催化剂,s/c 20,000/1),接着在50℃、4巴氢气下进行氢化。底物的转化在4小时后完成。该氢化产物的对映体过量通过手性HPLC测定为99.4%(柱的制造商:Chiracel;柱型:OD-H;流动相:95vol%正庚烷/5vol%2-丙醇-0.1ml三氟乙酸/1L该混合物;保留时间:75 kg of 4-monomethyl methylenesuccinate (520.4 mol) were introduced into 185 liters of methanol in a 1 m 3 steel vessel under protective gas. 19.0 g of (RophosARhCOD)CF 3 SO 3 (=26 mmol of prefabricated catalyst, s/c 20,000/1 ) dissolved in 2 liters of methanol were added, followed by hydrogenation at 50° C. under 4 bar of hydrogen. Substrate conversion was complete after 4 hours. The enantiomeric excess of the hydrogenated product was determined to be 99.4% by chiral HPLC (manufacturer of column: Chiracel; column type: OD-H; mobile phase: 95vol% n-heptane/5vol% 2-propanol-0.1ml Tris Fluoroacetic acid/1L of the mixture; retention time:

tR((R)-2-甲基琥珀酸4-甲基酯)=7.4分钟t R ((R)-4-methyl 2-methylsuccinate) = 7.4 minutes

tR((S)-2-甲基琥珀酸4-甲基酯)=16.7分钟)。t R ((S)-4-methyl 2-methylsuccinate) = 16.7 minutes).

向反应溶液中,分次加入总计22.2kg氢氧化锂一水合物,接着加入375kg甲基叔丁基醚,冷却到0℃。通过过滤将羧酸锂从获得的悬浮液中除去(收率:65.8kg)。其对映体过量(在释放后测定)>99.8%。To the reaction solution, a total of 22.2 kg of lithium hydroxide monohydrate was added in portions, followed by 375 kg of methyl tert-butyl ether, and cooled to 0°C. Lithium carboxylate was removed from the obtained suspension by filtration (yield: 65.8 kg). Its enantiomeric excess (determined after release) is >99.8%.

实施例5Example 5

现场制备预制催化剂(一般步骤)On-site preparation of prefabricated catalysts (general procedure)

将1.1当量的RophosA-Bistriflate盐(Rophos*2CF3SO3H)与1.1当量碱(优选胺如三乙胺、Hünig’s碱等)溶于甲醇,并且在-10℃下缓慢滴入1当量的金属源、优选(Rh[COD]2)X的溶液中,其中X=BF4,CF3SO3,SbF6,PF6,ClO4,BAr4。然后使该混合物达到室温。如果使用游离配体,则不加碱。Dissolve 1.1 equivalent of RophosA-Bistriflate salt (Rophos*2CF 3 SO 3 H) and 1.1 equivalent of base (preferably amine such as triethylamine, Hünig's base, etc.) in methanol, and slowly drop into 1 equivalent of metal at -10°C source, preferably a solution of (Rh[COD] 2 )X, where X=BF 4 , CF 3 SO 3 , SbF 6 , PF 6 , ClO 4 , BAr 4 . The mixture was then allowed to reach room temperature. If free ligand is used, no base is added.

Claims (17)

1. the method for a preparation formula (I) optically active alkyl succinic acid monoalkyl esters,
Figure F2005800228341C00011
Wherein D and E are H, C independently of one another 1-C 10Alkyl,
R is C 1-C 10Alkyl, phenyl or benzyl,
This method in the presence of the catalyzer that comprises formula (L) phospholane part,
Figure F2005800228341C00012
Wherein:
R 1Be hydrogen, C 1-C 6Alkyl or benzyl,
R 2Be C 1-C 6Alkyl or benzyl,
A is R 1Or
Condition be B=between two P atoms, have 1-5 carbon atom the connection base or
Cp-Fe-Cp,
Enantioselectivity ground hydrogenation of formula (II) compound
Figure F2005800228341C00021
Wherein D, E and R have above-mentioned meaning.
2. the method for claim 1, wherein D and E are that hydrogen and R are Me.
3. the method for claim 1 wherein is selected from part among Rophos A, the Rophos B as part (L):
Figure F2005800228341C00022
4. the method for claim 1, wherein said hydrogenation is carried out under the hydrogen pressure of 1-100 crust.
5. the method for claim 1, wherein said hydrogenation is carried out in methyl alcohol.
6. the method for claim 1, wherein said hydrogenation is carried out under 10 ℃-80 ℃.
7. the method for claim 1, use therein catalyzer is fixed.
8. the method for claim 1, wherein the reaction product that is obtained by hydrogenation (I) is converted into carboxylate salt and removes from this reaction mixture with this form.
9. method as claimed in claim 8, wherein said reaction product (I) precipitates from this reaction mixture with the form of carboxylic acid lithium.
10. the method for a preparation formula (I) optically active alkyl succinic acid monoalkyl esters,
Figure F2005800228341C00031
Wherein D and E are H, C independently of one another 1-C 10Alkyl,
R is C 1-C 10Alkyl, phenyl or benzyl,
This method in the presence of comprising the catalyzer that is selected from the part among Me-KetalPhos and the Me-f-KetalPhos,
Enantioselectivity ground hydrogenation of formula (II) compound
Wherein D, E and R have above-mentioned meaning.
11. method as claimed in claim 10, wherein D and E are that hydrogen and R are Me.
12. method as claimed in claim 10, wherein said hydrogenation is carried out under the hydrogen pressure of 1-100 crust.
13. method as claimed in claim 10, wherein said hydrogenation is carried out in methyl alcohol.
14. method as claimed in claim 10, wherein said hydrogenation is carried out under 10 ℃-80 ℃.
15. method as claimed in claim 10, use therein catalyzer is fixed.
16. method as claimed in claim 10, wherein the reaction product that is obtained by hydrogenation (I) is converted into carboxylate salt and removes from this reaction mixture with this form.
17. method as claimed in claim 16, wherein said reaction product (I) precipitates from this reaction mixture with the form of carboxylic acid lithium.
CN2005800228341A 2004-07-07 2005-07-06 Process for preparing optically active alkyl succinic acid monoalkyl esters Expired - Fee Related CN1980883B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE200410032968 DE102004032968A1 (en) 2004-07-07 2004-07-07 Preparation of optically active alkyl succinic acid monoalkyl esters comprising enantioselective hydrogenation of ester compound in presence of catalyst, which carries phospholane ligand
DE102004032968.0 2004-07-07
DE200510007750 DE102005007750A1 (en) 2005-02-18 2005-02-18 Preparation of optically active alkyl succinic acid monoalkyl esters comprising enantioselective hydrogenation of ester compound in presence of catalyst, which carries phospholane ligand
DE102005007750.1 2005-02-18
PCT/EP2005/007289 WO2006002999A2 (en) 2004-07-07 2005-07-06 Method for the production of optically active alkyl succinic acid monoalkyl esters

Publications (2)

Publication Number Publication Date
CN1980883A CN1980883A (en) 2007-06-13
CN1980883B true CN1980883B (en) 2010-05-26

Family

ID=35612752

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800228341A Expired - Fee Related CN1980883B (en) 2004-07-07 2005-07-06 Process for preparing optically active alkyl succinic acid monoalkyl esters

Country Status (2)

Country Link
CN (1) CN1980883B (en)
DE (1) DE102004032968A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043396A (en) * 1997-06-18 2000-03-28 Basf Aktiengesellschaft Preparation of optically active phospholanes, their metal complexes and use in asymmetric synthesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043396A (en) * 1997-06-18 2000-03-28 Basf Aktiengesellschaft Preparation of optically active phospholanes, their metal complexes and use in asymmetric synthesis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Duncan carmichael, et al.Hybrid P-chiral diphosphines for asymmetric hydrogenation.Chem. Commun. 3.1999,(3),261-262.
Duncan carmichael,et al.Hybrid P-chiral diphosphines for asymmetric hydrogenation.Chem.Commun. 3.1999,(3),261-262. *
Jens Holz, et al.Synthesis of a new class of functionalized chiralbisphospholane ligands and the application inenantioselective hydrogenations.J. org. chem63 22.1998,63(22),8031-8034.
Jens Holz,et al.Synthesis of a new class of functionalized chiralbisphospholane ligands and the application inenantioselective hydrogenations.J.org. chem63 22.1998,63(22),8031-8034. *

Also Published As

Publication number Publication date
DE102004032968A1 (en) 2006-02-09
CN1980883A (en) 2007-06-13

Similar Documents

Publication Publication Date Title
EP0295890B1 (en) Process of preparing optically active alcohol
Brown et al. Enantioselective catalytic transfer hydrogenation of α, β-unsaturated carboxylic acids with formates catalyzed by novel ruthenium phosphine complexes
JPH0641171A (en) Ferrocenyldiphosphine as ligand of homogeneous catalyst
CN108774271A (en) A kind of chiral nitrogen nitrogen phosphine tridentate ligand and its application based on ferrocene frame having ferrocene frame
JP3878703B2 (en) Chiral ruthenium complex, process for its preparation, and process for enantioselective transfer hydrogenation of prochiral ketones
CN106103413A (en) Process for producing optically active compounds
US6323353B1 (en) Complexes of transition metals with novel axial asymmetric compounds as the ligands
JP2731377B2 (en) Method for producing optically active alcohols
JPH0517491A (en) Optically active tertiary phosphine compound and transition metal complex comprising the same compound as ligand
KR20090091326A (en) Catalytic Asymmetric Hydrogenation Method
US6596887B2 (en) Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex
CN1980883B (en) Process for preparing optically active alkyl succinic acid monoalkyl esters
CN104725173B (en) Method for preparing optically active aldehyde or ketone and preparation method of catalyst thereof
EP0732337B1 (en) Optically active asymmetric diphosphine and process for producing optically active substance in its presence
US7015342B2 (en) Ferrocenyl ligands and method for the production of such ligands
US7601667B2 (en) Sulfonate catalyst and method of producing alcohol compound using the same
US7557240B2 (en) Method for the production of optically active alkyl succinic acid monoalkyl esters
RU2446154C2 (en) Sulphonylated diphenylethylene diamines, synthesis method thereof and use in transfer hydrogenation catalysis
JP4795559B2 (en) Method for producing l-menthol
JPH0816078B2 (en) Process for producing optically active phenylacetic acid derivative
JP3517591B2 (en) Production method of optically active amine
JPH05170718A (en) Method of enatioselectively synthesizing 2(r)- benzylsuccinic acid monoamide derivative
JP4658289B2 (en) Process for producing optically active fluorinated amino acid derivative
JP3494549B2 (en) A novel ruthenium complex having an amino acid as a ligand and an asymmetric hydrogenation method using the same
JPH11100370A (en) Production of optically active piperazine-2-carboxylic acid derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100526

Termination date: 20140706

EXPY Termination of patent right or utility model